Bristol Myers Squibb Capital Expenditures (CapEx) Growth & History (BMY)
Bristol Myers Squibb's capital expenditures (capex) was $1.31B for fiscal 2025.
View full Bristol Myers Squibb company overviewBristol Myers Squibb annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.31B | $63.0M | +5.05% |
| 2024 | 2024-12-31 | $1.25B | $39.0M | +3.23% |
| 2023 | 2023-12-31 | $1.21B | $91.0M | +8.14% |
| 2022 | 2022-12-31 | $1.12B | $145.0M | +14.90% |
| 2021 | 2021-12-31 | $973.0M | $220.0M | +29.22% |
| 2020 | 2020-12-31 | $753.0M | −$83.0M | −9.93% |
| 2019 | 2019-12-31 | $836.0M | −$115.0M | −12.09% |
| 2018 | 2018-12-31 | $951.0M | −$104.0M | −9.86% |
| 2017 | 2017-12-31 | $1.05B | −$160.0M | −13.17% |
| 2016 | 2016-12-31 | $1.22B | $395.0M | +48.17% |
| 2015 | 2015-12-31 | $820.0M | $294.0M | +55.89% |
| 2014 | 2014-12-31 | $526.0M | −$11.0M | −2.05% |
| 2013 | 2013-12-31 | $537.0M | −$11.0M | −2.01% |
| 2012 | 2012-12-31 | $548.0M | $181.0M | +49.32% |
| 2011 | 2011-12-31 | $367.0M | −$57.0M | −13.44% |
| 2010 | 2010-12-31 | $424.0M | −$306.0M | −41.92% |
| 2009 | 2009-12-31 | $730.0M | −$211.0M | −22.42% |
| 2008 | 2008-12-31 | $941.0M | $98.0M | +11.63% |
| 2007 | 2007-12-31 | $843.0M | — | — |
Bristol Myers Squibb quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $305.0M | −$56.0M | −15.51% |
| Q1 2026 | 2026-03-31 | $347.0M | $87.0M | +33.46% |
| Q4 2025 | 2025-12-31 | $370.0M | −$8.0M | −2.12% |
| Q3 2025 | 2025-09-30 | $320.0M | −$4.0M | −1.23% |
| Q2 2025 | 2025-06-30 | $361.0M | $99.0M | +37.79% |
| Q1 2025 | 2025-03-31 | $260.0M | −$24.0M | −8.45% |
| Q4 2024 | 2024-12-31 | $378.0M | $48.0M | +14.55% |
| Q3 2024 | 2024-09-30 | $324.0M | −$18.0M | −5.26% |
| Q2 2024 | 2024-06-30 | $262.0M | $3.0M | +1.16% |
| Q1 2024 | 2024-03-31 | $284.0M | $6.0M | +2.16% |
| Q4 2023 | 2023-12-31 | $330.0M | −$16.0M | −4.62% |
| Q3 2023 | 2023-09-30 | $342.0M | $95.0M | +38.46% |
| Q2 2023 | 2023-06-30 | $259.0M | −$13.0M | −4.78% |
| Q1 2023 | 2023-03-31 | $278.0M | $25.0M | +9.88% |
| Q4 2022 | 2022-12-31 | $346.0M | $26.0M | +8.13% |
| Q3 2022 | 2022-09-30 | $247.0M | −$23.0M | −8.52% |
| Q2 2022 | 2022-06-30 | $272.0M | $62.0M | +29.52% |
| Q1 2022 | 2022-03-31 | $253.0M | $80.0M | +46.24% |
| Q4 2021 | 2021-12-31 | $320.0M | $37.0M | +13.07% |
| Q3 2021 | 2021-09-30 | $270.0M | $117.0M | +76.47% |
| Q2 2021 | 2021-06-30 | $210.0M | $79.0M | +60.31% |
| Q1 2021 | 2021-03-31 | $173.0M | −$13.0M | −6.99% |
| Q4 2020 | 2020-12-31 | $283.0M | $32.0M | +12.75% |
| Q3 2020 | 2020-09-30 | $153.0M | −$37.0M | −19.47% |
| Q2 2020 | 2020-06-30 | $131.0M | −$60.0M | −31.41% |
| Q1 2020 | 2020-03-31 | $186.0M | −$18.0M | −8.82% |
| Q4 2019 | 2019-12-31 | $251.0M | −$39.0M | −13.45% |
| Q3 2019 | 2019-09-30 | $190.0M | −$34.0M | −15.18% |
| Q2 2019 | 2019-06-30 | $191.0M | −$7.0M | −3.54% |
| Q1 2019 | 2019-03-31 | $204.0M | −$35.0M | −14.64% |
| Q4 2018 | 2018-12-31 | $290.0M | $36.0M | +14.17% |
| Q3 2018 | 2018-09-30 | $224.0M | −$38.0M | −14.50% |
| Q2 2018 | 2018-06-30 | $198.0M | −$50.0M | −20.16% |
| Q1 2018 | 2018-03-31 | $239.0M | −$52.0M | −17.87% |
| Q4 2017 | 2017-12-31 | $254.0M | −$117.0M | −31.54% |
| Q3 2017 | 2017-09-30 | $262.0M | −$79.0M | −23.17% |
| Q2 2017 | 2017-06-30 | $248.0M | −$13.0M | −4.98% |
| Q1 2017 | 2017-03-31 | $291.0M | $49.0M | +20.25% |
| Q4 2016 | 2016-12-31 | $371.0M | $86.0M | +30.18% |
| Q3 2016 | 2016-09-30 | $341.0M | $107.0M | +45.73% |
| Q2 2016 | 2016-06-30 | $261.0M | $96.0M | +58.18% |
| Q1 2016 | 2016-03-31 | $242.0M | $106.0M | +77.94% |
| Q4 2015 | 2015-12-31 | $285.0M | $94.0M | +49.21% |
| Q3 2015 | 2015-09-30 | $234.0M | $127.0M | +118.69% |
| Q2 2015 | 2015-06-30 | $165.0M | $55.0M | +50.00% |
| Q1 2015 | 2015-03-31 | $136.0M | $18.0M | +15.25% |
| Q4 2014 | 2014-12-31 | $191.0M | −$9.0M | −4.50% |
| Q3 2014 | 2014-09-30 | $107.0M | −$17.0M | −13.71% |
| Q2 2014 | 2014-06-30 | $110.0M | $12.0M | +12.24% |
| Q1 2014 | 2014-03-31 | $118.0M | $3.0M | +2.61% |
| Q4 2013 | 2013-12-31 | $200.0M | $25.0M | +14.29% |
| Q3 2013 | 2013-09-30 | $124.0M | −$13.0M | −9.49% |
| Q2 2013 | 2013-06-30 | $98.0M | −$15.0M | −13.27% |
| Q1 2013 | 2013-03-31 | $115.0M | −$8.0M | −6.50% |
| Q4 2012 | 2012-12-31 | $175.0M | $41.0M | +30.60% |
| Q3 2012 | 2012-09-30 | $137.0M | $53.0M | +63.10% |
| Q2 2012 | 2012-06-30 | $113.0M | $39.0M | +52.70% |
| Q1 2012 | 2012-03-31 | $123.0M | $48.0M | +64.00% |
| Q4 2011 | 2011-12-31 | $134.0M | $9.0M | +7.20% |
| Q3 2011 | 2011-09-30 | $84.0M | −$5.0M | −5.62% |
| Q2 2011 | 2011-06-30 | $74.0M | −$7.0M | −8.64% |
| Q1 2011 | 2011-03-31 | $75.0M | −$54.0M | −41.86% |
| Q4 2010 | 2010-12-31 | $125.0M | −$71.0M | −36.22% |
| Q3 2010 | 2010-09-30 | $89.0M | −$80.0M | −47.34% |
| Q2 2010 | 2010-06-30 | $81.0M | −$83.0M | −50.61% |
| Q1 2010 | 2010-03-31 | $129.0M | −$72.0M | −35.82% |
| Q4 2009 | 2009-12-31 | $196.0M | — | — |
| Q3 2009 | 2009-09-30 | $169.0M | −$27.0M | −13.78% |
| Q2 2009 | 2009-06-30 | $164.0M | — | — |
| Q1 2009 | 2009-03-31 | $201.0M | — | — |
| Q3 2008 | 2008-09-30 | $196.0M | — | — |
Bristol Myers Squibb capital expenditures (capex) trends
Over the last five fiscal years, Bristol Myers Squibb's capital expenditures (capex) increased from $753.0M to $1.31B, a change of $558.0M. The latest reported quarter, Q2 2026, shows $305.0M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bristol Myers Squibb source filings ↗